NXY-059
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cerebral Stroke
Conditions
Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke, Ischemic Attack, Transient
Trial Timeline
May 1, 2003 → Sep 1, 2006
NCT ID
NCT00061022About NXY-059
NXY-059 is a phase 3 stage product being developed by AstraZeneca for Cerebral Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT00061022. Target conditions include Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00075959 | Phase 2 | Completed |
| NCT00119626 | Phase 3 | Completed |
| NCT00061022 | Phase 3 | Completed |
Competing Products
20 competing products in Cerebral Stroke
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mouse nerve growth factor | Sun Pharmaceutical | Approved | 85 |
| Edaravone Dexborneol + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Oral Glycopyrrolate Liquid | Shionogi | Phase 3 | 77 |
| recombinant human erythropoietin alfa + 0.9% NaCl | Johnson & Johnson | Phase 2/3 | 65 |
| UDI-001 | Rohto Pharmaceutical | Phase 1/2 | 41 |
| NXY-059 | AstraZeneca | Phase 2 | 52 |
| Rosuvastatin | AstraZeneca | Approved | 85 |
| NXY-059 | AstraZeneca | Phase 3 | 77 |
| Comparator: Placebo + Comparator: MK0724 | Merck | Phase 2 | 52 |
| Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg | Merck | Phase 2 | 52 |
| Recombinant Factor VIIa + Biological/Vaccine: Placebo | Novo Nordisk | Phase 3 | 76 |
| Recombinant Activated Factor VII (rFVIIa) + Placebo | Novo Nordisk | Phase 3 | 76 |
| Ponezumab | Pfizer | Phase 2 | 51 |
| PF-05230907 | Pfizer | Phase 1 | 32 |
| Azithromycin + Pyrimethamine + Leucovorin calcium | Pfizer | Phase 1 | 32 |
| clopidogrel (SR25990C) | Sanofi | Approved | 84 |
| Intrarectal quinine | Sanofi | Phase 3 | 76 |
| Piracetam | UCB | Approved | 82 |
| Placebo + ALN-APP | Alnylam Pharmaceuticals | Phase 2 | 49 |
| CN-105 | Tiantan Bio | Phase 2 | 49 |